SQZ Biotechnologies (SQZ) Competitors

SQZ Biotechnologies logo
$0.02 0.00 (0.00%)
As of 11/17/2026

SQZ vs. CODX, REVB, CRIS, DCOY, and BRTX

Should you buy SQZ Biotechnologies stock or one of its competitors? SQZ Biotechnologies's main competitors and comparable companies include Co-Diagnostics (CODX), Revelation Biosciences (REVB), Curis (CRIS), Decoy Therapeutics (DCOY), and Biorestorative Therapies (BRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SQZ Biotechnologies compare to Co-Diagnostics?

SQZ Biotechnologies (NYSE:SQZ) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Co-Diagnostics has lower revenue, but higher earnings than SQZ Biotechnologies. Co-Diagnostics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Co-Diagnostics$620K3.32-$46.90M-$10.32N/A

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by insiders. Comparatively, 1.7% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Co-Diagnostics has a consensus target price of $45.00, suggesting a potential upside of 22,859.18%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than SQZ Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Co-Diagnostics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

In the previous week, Co-Diagnostics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Co-Diagnostics and 0 mentions for SQZ Biotechnologies. Co-Diagnostics' average media sentiment score of 0.63 beat SQZ Biotechnologies' score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Co-Diagnostics Positive

SQZ Biotechnologies has a net margin of -369.96% compared to Co-Diagnostics' net margin of -5,530.54%. SQZ Biotechnologies' return on equity of -119.83% beat Co-Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Co-Diagnostics -5,530.54%-322.92%-251.11%

SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 3.15, suggesting that its stock price is 215% more volatile than the broader market.

Summary

SQZ Biotechnologies and Co-Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Revelation Biosciences has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -124.23% -98.96%
SQZ Biotechnologies -369.96%-119.83%-59.90%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Revelation Biosciences has higher earnings, but lower revenue than SQZ Biotechnologies. Revelation Biosciences is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Revelation Biosciences has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

In the previous week, Revelation Biosciences had 10 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 10 mentions for Revelation Biosciences and 0 mentions for SQZ Biotechnologies. Revelation Biosciences' average media sentiment score of 0.46 beat SQZ Biotechnologies' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Revelation Biosciences Neutral
SQZ Biotechnologies Neutral

Summary

SQZ Biotechnologies beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Curis?

Curis (NASDAQ:CRIS) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

30.0% of Curis shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 1.5% of Curis shares are owned by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Curis has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Curis' return on equity.

Company Net Margins Return on Equity Return on Assets
CurisN/A -767.00% -222.98%
SQZ Biotechnologies -369.96%-119.83%-59.90%

Curis currently has a consensus price target of $43.00, indicating a potential upside of 7,836.51%. Given Curis' stronger consensus rating and higher probable upside, research analysts clearly believe Curis is more favorable than SQZ Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Curis has higher earnings, but lower revenue than SQZ Biotechnologies. Curis is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$9.44M0.24-$7.58M-$6.36N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Curis has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

In the previous week, Curis had 9 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 9 mentions for Curis and 0 mentions for SQZ Biotechnologies. Curis' average media sentiment score of 0.86 beat SQZ Biotechnologies' score of 0.00 indicating that Curis is being referred to more favorably in the media.

Company Overall Sentiment
Curis Positive
SQZ Biotechnologies Neutral

Summary

Curis beats SQZ Biotechnologies on 9 of the 15 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Decoy Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

In the previous week, Decoy Therapeutics had 3 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 3 mentions for Decoy Therapeutics and 0 mentions for SQZ Biotechnologies. Decoy Therapeutics' average media sentiment score of 0.81 beat SQZ Biotechnologies' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Decoy Therapeutics Positive
SQZ Biotechnologies Neutral

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Decoy Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 3,059.89%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than SQZ Biotechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decoy Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Decoy Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Decoy Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decoy TherapeuticsN/AN/A-$12.52M-$30.37N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Decoy Therapeutics has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Decoy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Decoy TherapeuticsN/A -355.58% -177.75%
SQZ Biotechnologies -369.96%-119.83%-59.90%

Summary

Decoy Therapeutics and SQZ Biotechnologies tied by winning 7 of the 14 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, Biorestorative Therapies had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Biorestorative Therapies and 0 mentions for SQZ Biotechnologies. Biorestorative Therapies' average media sentiment score of 0.21 beat SQZ Biotechnologies' score of 0.00 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
SQZ Biotechnologies Neutral

Biorestorative Therapies has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SQZ Biotechnologies has a net margin of -369.96% compared to Biorestorative Therapies' net margin of -3,088.27%. SQZ Biotechnologies' return on equity of -119.83% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
SQZ Biotechnologies -369.96%-119.83%-59.90%

Biorestorative Therapies has higher earnings, but lower revenue than SQZ Biotechnologies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K5.14-$14.24M-$21.40N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Summary

SQZ Biotechnologies beats Biorestorative Therapies on 7 of the 13 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SQZ vs. The Competition

MetricSQZ BiotechnologiesBiotechnology IndustryHealthcare SectorNYSE Exchange
Market Cap$708K$4.03B$7.72B$22.19B
Dividend YieldN/A3.63%2.47%3.86%
P/E Ratio-0.0125.9032.4824.44
Price / Sales0.0415.668.383.40
Price / CashN/A22.7220.8515.36
Price / Book0.014.164.443.64
Net Income-$79.46M-$23.99M$3.51B$1.07B
7 Day PerformanceN/A-8.45%-6.54%-4.52%
1 Month PerformanceN/A-6.55%-4.93%-2.75%
1 Year PerformanceN/A-6.56%-1.68%5.41%

SQZ Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SQZ
SQZ Biotechnologies
N/A$0.02
flat
N/A+0.0%$708K$18.16MN/A1,620
CODX
Co-Diagnostics
1.5857 of 5 stars
$0.28
-3.8%
$45.00
+16,098.7%
-97.9%$2.74M$620KN/A115
REVB
Revelation Biosciences
0.7758 of 5 stars
$4.15
+5.4%
N/A-84.0%$2.69MN/AN/A9
CRIS
Curis
2.9298 of 5 stars
$0.59
-9.4%
$43.00
+7,169.7%
-97.8%$2.68M$9.44MN/A24
DCOY
Decoy Therapeutics
2.3542 of 5 stars
$1.09
-1.8%
$30.00
+2,652.3%
N/A$2.65MN/AN/A11

Related Companies and Tools


This page (NYSE:SQZ) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners